The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/II study of the CXCR2 inhibitor, AZD5069, in combination with durvalumab, in patients (pts) with advanced hepatocellular carcinoma (HCC).
 
T.R. Jeffry Evans
Honoraria - Ascelia (Inst); AstraZeneca (Inst); Bicycle Therapeutics (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst)
Consulting or Advisory Role - Karus Therapeutics (Inst)
Speakers' Bureau - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Eisai (Inst); Medivir (Inst); Merck Sharp & Dohme (Inst); Nucana (Inst); Roche/Genentech (Inst); United Medical (Inst)
Research Funding - Adaptimmune (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Athenex (Inst); Avacta Life Sciences (Inst); Basilea (Inst); Beigene (Inst); Berg Pharma (Inst); Bicycle Therapeutics (Inst); BiolineRx (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Clovis Oncology (Inst); Codiak BioSciences (Inst); CytomX Therapeutics (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Halozyme (Inst); Immunocore (Inst); iOnctura (Inst); Iovance Biotherapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); Lilly (Inst); Medivir (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); MiNA Therapeutics (Inst); Modulate Pharma (Inst); Novartis (Inst); Nucana (Inst); Nurix (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Sierra Pharma (Inst); Starpharma (Inst); T3 Pharmaceuticals (Inst); UCB (Inst); Verastem (Inst); Vertex (Inst)
Expert Testimony - Medivir (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; Eisai; Merck Sharp & Dohme; Nucana; Pierre Fabre
Other Relationship - Genmab (Inst)
 
Bristi Basu
Consulting or Advisory Role - Eisai (Inst); GenMab (Inst); Roche (Inst)
Speakers' Bureau - Eisai Europe; Eisai Europe (Inst)
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Roche
 
Richard Hubner
Consulting or Advisory Role - BeiGene; Ipsen; Novartis
Travel, Accommodations, Expenses - Roche
 
Yuk Ting Ma
Honoraria - Boston Scientific
Consulting or Advisory Role - AstraZeneca/MedImmune; Eisai; Faron Pharmaceuticals; Ipsen; Roche
Research Funding - AstraZeneca/Merck (Inst); Eisai (Inst); Faron Pharmaceuticals (Inst); MINA THERAPEUTICS (Inst)
 
Tim Meyer
Consulting or Advisory Role - Bayer; Beigene; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Daniel H. Palmer
Consulting or Advisory Role - AstraZeneca; BMS (Inst); Boston Scientific; Eisai; MSD; Roche; Sirtex Medical; Viatris
Research Funding - AstraZeneca; Bayer; BMS; Nucana; Sirtex Medical
 
David J. James Pinato
Honoraria - Avammune; Bristol-Myers Squibb; Da Volterra; Mursla Bio; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Da Volterra; Eisai; H3 Biomedicine; Ipsen; Mina Therapeutics; Roche
Speakers' Bureau - Bayer; Falk Pharma; Roche; ViiV Healthcare
Research Funding - Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; MSD Oncology
Other Relationship - Wiley
 
Elizabeth Ruth Plummer
Honoraria - Amgen (I); AstraZeneca/MedImmune; Bristol-Myers Squibb; Novartis Pharmaceuticals UK Ltd.; Pfizer (I); Tesaro
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Biosceptre; Bristol-Myers Squibb/Medarex; CV6 Therapeutics; Cybrexa Therapeutics; Ellipses Pharma; Genmab; Immunocore; Medivir; Novartis; Novartis; Onxeo; Pierre Fabre; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
Other Relationship - Alligator Bioscience; GlaxoSmithKline; Sotio
 
Paul J. Ross
Stock and Other Ownership Interests - Perci Health
Honoraria - AstraZeneca; Merck; Roche; Sirtex Medical
Consulting or Advisory Role - Amgen; AstraZeneca; Boston Scientific; Roche; Sirtex Medical
Speakers' Bureau - Amgen; Boston Scientific; Eisai; Merck; Roche; Servier
Research Funding - Bayer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Ipsen; Roche
 
Adel Samson
Research Funding - Stratosvir; Transgene (Inst); Transgene (Inst)
 
Debashis Sarker
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - AAA HealthCare; Bayer; Eisai; Ipsen; Novartis; Roche; Sirtex Medical; Surface Oncology; UCB (Inst)
Speakers' Bureau - AstraZeneca; Bayer; Eisai
Research Funding - UCB (Inst)
Travel, Accommodations, Expenses - MiNA Therapeutics
(OPTIONAL) Uncompensated Relationships - Medivir; MINA THERAPEUTICS
 
Timothy Kendall
Honoraria - Incyte
Consulting or Advisory Role - Clinnovate Health; Perspectum Diagnostics; Resolution Therapeutics
Speakers' Bureau - Incyte
 
Christopher Bellamy
No Relationships to Disclose
 
Helen L Reeves
Consulting or Advisory Role - Boston Scientific (Inst); Sirtex Medical (Inst)
 
Fiona Thomson
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Merck Sharp & Dohme
Research Funding - AstraZeneca
 
Claire A Lawless
No Relationships to Disclose
 
Jamie Stobo
No Relationships to Disclose
 
Owen J Sansom
No Relationships to Disclose
 
Derek A. Mann
Employment - FibroFind
Leadership - FibroFind
Stock and Other Ownership Interests - FibroFind
Research Funding - FibroFind; GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - FibroFind
 
Thomas G Bird
Consulting or Advisory Role - Roche